Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 812 results for "merck co"

Merck files for FDA approval of Keytruda in lung cancer

(Reuters) - Merck & Co Inc said on Sunday it has submitted an application to the U.S. Food and Drug Administration for its drug Keytruda as a treatment for advanced non-small cell lung cancer, the most common form of the disease. Keytruda, also ... Reuters, 3 hours ago
Merck Cancer Drug Shines Against Skin, Lung Cancer, 36 minutes ago

154 images for merck co

Njbiz, 3 hours ago
CNBC, 2 hours ago
Jutia Group, 3 days ago
Bio Spectrum Asia, 1 week ago
Drug Discovery and Development, 1 week ago
Schaeffers Research, 1 week ago
Pharma Letter, 8 hours ago
Jutia Group, 1 month ago, 1 month ago, 3 weeks ago

Merck Drug Shows Improved Odds for Melanoma Patients

Merck & Co.'s new cancer drug Keytruda improved the survival odds of patients with the skin cancer melanoma compared with Bristol-Myers Squibb Co.'s Yervoy, in the first head-to-head study of a new wave of drugs that harness the body's immune system ...
 Austin American Statesman2 hours ago Merck's Keytruda Shows Improved Survival Odds for Melanoma Patients  4 Traders2 hours ago Merck''s Keytruda Shows Improved Survival Odds for Melanoma Patients  Nasdaq2 hours ago

Merck's Keytruda shrinks lung cancer tumors, FDA approval sought

(Reuters) - Merck & Co Inc's Keytruda, approved for treating melanoma, was shown in a trial to shrink tumors in nearly half of advanced lung cancer patients with high levels of a protein used by tumors to evade the body's own disease-fighting cells.
 Reuters3 hours ago

Merck receives two new breakthrough therapy designations for HCV drug from FDA

Merck has received two new breakthrough therapy designations from the FDA for grazoprevir/elbasvir, an investigational single tablet regimen, for the treatment of patients with chronic HCV genotype 4, or GT4, infection, and for the treatment of ...
 Individual.com1 day ago FDA gives Merck Breakthrough Therapy designation to treat chronic hepatitis C virus in dialysis patients  NephrologyNews.com1 week ago Merck's HCV Combo Drug Gets Two Breakthrough Status - Analyst Blog  Zacks.com1 week ago FDA Grants Breakthrough Designations to Merck's Hepatitis C Candidate  Pharmacy Times1 week ago

Merck (MRK) Showing Bearish Technicals With Resistance At $58.64

Merck & Co Inc. ("MRK) presents a trading opportunity that offers a 2.92% return in just 63 days. A covered call on Merck at the $57.50 level expiring on Jun. '15 offers an assigned return rate of ...
 Individual.com1 day ago
SPi World News

Fitch Downgrades Merck

Fitch Ratings has downgraded pharmaceutical company Merck & Co's rating to A from A+, though it also revised the outlook to stable from negative, citing improving margins. Shares of Merck were recently down less than 1% in midday trading. ...
 Morningstar.com5 days ago Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable  Reuters UK5 days ago Careful, European drugmakers. Fitch says M&A may be a bit too heated  FiercePharma2 days ago

Merck (MRK) Trading Near $56.00 Support Level

(FreshBrewedMedia) The patented options-trade picking algorithms used by found a trading opportunity with Merck & Co Inc. ( MRK ) that should provide
 Individual.com4 days ago Merck (MRK) Trading Near $58.44 Resistance Level  Individual.com1 week ago Merck (MRK) Trading Near $56.80 Support Level  Individual.com1 week ago

CNBC Excerpts: CNBC Exclusive: Merck Chairman & CEO Ken Frazier Speaks with CNBC's Meg Tirrell Today on "Power Lunch"

WHEN: Today, Thursday, April 16th WHERE: CNBC's "" Following are excerpts from the unofficial transcript of a CNBC EXCLUSIVE interview with Merck Chairman & CEO Ken Frazier on CNBC's "Power Lunch" (M-F, 1PM-3PM ET) today.
 CNBC2 days ago
Bio Spectrum Asia

MERCK KGAA : Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORIĀ® crizotinib

By a News Reporter-Staff News Editor at Pharma Business Week -- Merck KGaA, Darmstadt , Germany , and Pfizer Inc. , New York , US, announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizer's anaplastic ...
 4 Traders3 days ago Pfizer, Merck KGaA sign pact to co-promote ALK inhibitor Xalkori  PharmaBiz1 week ago Merck, Pfizer to co-market potential cancer drug  Bio Spectrum Asia1 week ago Merck and Pfizer to co-promote cancer drug  Pharmafocus1 week ago

Potential Merck (MRK) Trade Has 5.85% Downside Protection

After FridayaEUR(TM)s trading in Merck & Co Inc. ("MRK)'s patented algorithms uncovered a trade that offers a 2.04% return or 7.84% on an annualized basis (for comparison ...
 Individual.com5 days ago Potential Merck (MRK) Trade Has 3.51% Downside Protection  Individual.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less